ECR 2022
iBiopsy®’s Median team will be exhibiting at the ECR on July 13-17, in Vienna. Meet us at booth #AI-29, we will be presenting the latest updates of iBiopsy®, our unique end-to-end AI/ML tech_based Software as Medical Device (SaMD).
Median's latest news
Fredrik Brag, CEO and founder of Median, provides additional insights on iBiopsy ® Lung Cancer Screening CADe/CADx Software as Medical Device (in French).
Latest press releases
Our Winter Corporate Newsletter
Webinars
Advancing treatments of the future
Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.
Enhancing imaging diagnostic accuracy
Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.
Delivering value
Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.